Indivior PLC completed a $295 million payment to the U.S. Department of Justice on November 20, 2025, fully extinguishing a legacy regulatory obligation that had lingered on the company’s balance sheet for years. The cash‑on‑hand transaction removed a material liability, simplified the capital structure, and eliminated the ongoing compliance and regulatory scrutiny that had accompanied the DOJ matter.
Indivior’s Q3 2025 financial results reflected a strong earnings beat, with earnings per share of $0.72 versus consensus estimates of $0.38—a $0.34 or 90% upside. Total revenue reached $314 million, up 21% from the $257.66 million forecast, driven by robust sales of its flagship opioid‑use‑disorder treatment, SUBLOCADE. The company’s gross margin of 80.78% and net margin of 10.42% in recent analysis underscore efficient cost management, although the Q3 net margin of 6.65% indicates some compression from higher operating expenses and investment in growth initiatives.
The OUD portfolio remains the core of Indivior’s revenue engine. SUBLOCADE, a monthly injectable buprenorphine therapy, continued to expand market share, supported by a nationwide “Move Forward in Recovery” direct‑to‑consumer campaign. Pricing stability for the complementary SUBOXONE Film product helped maintain revenue momentum, while the company’s focus on operational efficiency kept cost growth in check. These factors collectively explain the revenue and earnings outperformance relative to analysts’ expectations.
Management raised its full‑year 2025 revenue guidance, reflecting confidence in sustained demand for OUD treatments and the positive trajectory of SUBLOCADE sales. The company also reiterated its commitment to cost discipline and strategic investments in high‑return verticals, signaling a balanced outlook for profitability and growth. The removal of the DOJ liability further strengthens the company’s financial flexibility, positioning it to allocate resources toward its core portfolio and future initiatives.
The settlement and earnings beat were well received by the market. Indivior’s share price reached a new 52‑week high of $32.45 on the day of the announcement, and the consensus analyst rating was “Strong Buy” with an average price target of $32.50. Several analysts raised their targets, citing the company’s strong guidance, margin profile, and the de‑risking effect of the DOJ resolution.
CEO Joe Ciaffoni said, “We are pleased to reach this important milestone that concludes the legacy DOJ matter. It removes a significant liability and simplifies our capital structure.” CFO Ryan Preblick highlighted the continued growth of SUBLOCADE and the stability of SUBOXONE Film pricing as key drivers for the raised 2025 guidance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.